Pharmacokinetics and pharmacodynamics of estramustine phosphate

Clinical Pharmacokinetics

Volumn 34, Issue 2, 1998, Pages 163-172

  Bergenheim, A Tommy ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ESTRAMUSTINE PHOSPHATE;

ARTICLE; BREAST CARCINOMA; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG MECHANISM; DRUG UPTAKE; GLIOMA; GYNECOMASTIA; ISCHEMIC HEART DISEASE; NAUSEA; PHARMACODYNAMICS; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOSENSITIZATION; VEIN THROMBOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CARRIER PROTEINS; ESTRAMUSTINE; HUMANS; IMPOTENCE; MALE; PROSTATE; PROSTATIC SECRETORY PROTEINS; RADIATION-PROTECTIVE AGENTS;

EID: 0031910862     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834020-00004     Document Type: Article

References (94)

1. von Schoultz E, Lundblad D, Bergh J, et al. Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer 1488; 58: 326-9
2. Piepmeier JM, Keefe DL, Weinstein MA, et al. Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 1993; 32: 422-31
3. Bergenheim AT. Estramustine-binding protein and cytotoxic effect of estramustine in glioma [dissertation]. Umeå: University of Umea, 1994
4. Bergenheim AT, Olofsson A, Stahl A, et al. Prognostic implications of estramustine-binding protein in astrocytoma. Int J Oncol 1995; 7: 349-52
5. Yoshida D, Cornell-Bell A, Piepmeier JM. Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes. Neurosurgery 1994; 34: 863-8
6. Forsgren B, Björk P, Carlström K, et al. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivate of estradiol-17β. Proc Natl Acad Sci 1974; 76: 3149-53
7. Björk P, Fritjofsson A, Hartley-Asp B. Uptake and binding of estramustine and estromustine, metabolites of estramustine phosphate (Estracyt), in the human prostate, and new aspects on the cytotoxic activity of estramustine phosphate in vitro. In: Harzmann R, editor. Experimentelle urologie. Berlin: Springer Verlag, 1985: 341-53
8. Björk P, Flüchter S, Nelde H. Estramustine-binding protein: a marker for effect of therapy in prostatic carcinoma? Scand J Urol Nephrol 1988; Suppl. 107: 59-64
9. Björk P, Borg A, Fernö M, et al. Expression and partial characterization of estramustine-binding protein in human breast cancer and malignant melanoma Anticancer Res 1991; 11: 1173-82
10. Norlén BJ, Andersson S-B, Björk P, et al. Uptake of estramustine phosphate (Estracyt) metabolites in prostatic cancer. J Urol 1988; 140: 1058-62
11. Flüchter SH, Nelde HJ, Björk P, et al. Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: an immunohistochemical study. Prostate 1989; 14: 27-43
12. von Schoultz E, Bergenheim T, Grankvist K, et al. Estramustine binding protein in human brain tumor tissue. J Neurosurg 1991; 74: 962-4
13. von Schoultz E, Carlström K, Henriksson K, et al. Estramustine-binding protein in primary tumors and metastasis of malignant melanoma. Melanoma Res 1994; 4: 401-5
14. Bergenheim AT, Björk P, Bergh J, et al. Estramustine-binding protein and specific binding of estramustine in astrocytoma. Cancer Res 1994; 54: 4974-9
15. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate 1984; 5: 93-100
16. Stearns M, Tew K. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985; 45: 3891-7
17. Eklöx S, Nilsson S, Larsson A, et al. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992; 20: 43-50
18. Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986; 9: 387-95
19. Grankvist K, von Schoultz E, Henriksson R. New aspects on the cytotoxicity of estramustine-involvement of free-oxygen radicals. Int J Exp Clin Chemother 1988; 1: 37-42
20. Henriksson R, Bjermer L, von Schoultz E, et al. The effect of estramustine on microtubuli is different from the direct action via oxygen radicals on DNA and cell membrane. Anticancer Res 1990; 10: 303-10
21. von Schoultz E, Grankvist K, Gustavsson H, et al. Effects of estramustine on DNA and cell membrane in malignant glioma cells. Acta Oncol 1991; 30: 719-23
22. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993; 149: 1622-5
23. Sandström PE, Jonsson Ö, Grankvist K, et al. Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma, and pulmonary carcinoma cell lines. Eur J Cancer 1994; 12: 1822-6
24. Vallbo C, Bergenheim T, Bergh A, et al. DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain: suggesting an apoptotic cell death. Br J Cancer 1995; 71: 717-20
25. Bergenheim AT, Zackrisson B, Elfverson J, et al. Radiosensitizing effect of estramustine in gliomas in vitro and in vivo. J Neurooncol 1995; 23: 191-200
26. Widmark A, Bergh A, Damber J-E, et al. Estramustine potentierar straleffekten av prostatacancer hos ratta [abstract]. Swedish Medical Society Annual Meeting. Proc Swedish Physicans Assoc 1991; 100 (2): 268
27. Widmark A, Damber J-E, Bergh A, et al. Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma. Prostate 1994; 24: 79-83
28. Yoshida D, Piepmeier J, Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res 1994; 54: 1415-7
29. Folca PJ, Glascock RF, Irvine WT. Studies with tritium-labelled hexoestrol in advanced breast cancer. Lancet 1961; 11: 796
30. Fex HJ, Högberg KB, Könyves I, et al. Certain steroid N-bis-(halo-ethyl)-carbamates, US patent 3,299,104. 1967 Jan
31. Fex H. Högiberg B, Könyves I. Estramustine phosphate: historical review. J Urol 1984; 23: 4-5
32. Danielli JF, Br Emp Cancer Campaign Annual Rept, 1959: 575
33. Groupe Europeen du Cancer du Sein. Essai clinique du phénol bis(2-chloroéthyl) carbamate d'oestradiol dans le cancer mammaire en phase avancée. Eur J Cancer 1969; 5: 1-4
34. Plym-Forshell G, Nilsson H. The distribution of radioactivity after administration of labelled estramustine phosphate (Estracyl), estradio-17β-phosphate and estradiol to rats. Acta Pharmacol Toxicol 1974; 35 Suppl. 1: 28
35. Jönsson G. Cytotoxic agents in the treatment of prostatic carcinoma. Life Sci Monogr 1969; 1: 145-59
36. Klein D. Behandlung mit estramustinphosphat bei fortgeschrittenen Prostatacarzinomen. Wiener Med Wöchenschrift 1971; 122: 458-60
37. Lindberg B. Treatment of rapidly progressing prostatic carcinoma with estracyt. J Urol 1972; 108: 303-6
38. Jonsson G, Olsson AM, Luttrop W, et al. Treatment of prostatic carcinoma with various types of estrogen derivatives. Vitam Horm 1975; 33: 351-76
39. Forsgren B, Gustafsson J-A, Pousette A, et al. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivate of 17 β-estradiol. Cancer Res 1979; 39: 5155-64
40. Björk P, Forsgren B, Gustafsson J-A, et al. Partial characterization and 'quantitation' of a human prostatic estramustine binding protein. Cancer Res 1982; 42: 1935-42
41. Forsgren B, Björk P. Specific binding of estramustine to prostatic proteins. Urology 1984; 23 Suppl. 6: 34-8
42. Tew K, Hartley-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. J Urol 1984; 23: 28-33
43. Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 1987; 15: 155-60
44. von Schoultz E, Lundgren E, Henriksson R. Effects of estramustine and its constituents on human malignant glioma cells. Anticancer Res 1990; 10: 693-6
45. Gunnarsson PO, Andersson S-B, Johansson S-A, et al. Pharmacokinetics of estramustine phosphate (Estracyt®) in prostatic cancer patients. Eur J Clin Pharmacol 1984; 26: 113-9
46. Dixon R, Brooks M, Gill G. Estramustine phosphate: plasma concentrations of its metabolites following oral administration to man, rat, and dog. Res Comm Chem Pathol Pharmacol 1980; 27: 17-29
47. Andersson SB, Gunnarsson PO, Nilsson T, et al. Metabolism of estramustine phosphate in patients with prostatic carcinoma. Eur J Drug Metab Pharmacokinet 1981; 6: 149-54
48. Gunnarsson P-O, Plym-Forshell G, Fritjofsson A, et al. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different closes of estramustine phosphate (Estracyt®). Scand J Urol Nephrol 1981; 15: 201-6
49. Bergenheim AT, Gunnarsson PO, Edman K, et al. Uptake and retention of estramustine and the presence of estramustine-binding protein in malignant brain tumors in humans. Br J Cancer 1993; 67: 358-61
50. Kirdani RY, Mittelman A, Murphy GP, et al. Studies on phenolic steroids in human subjects. XIV: fate of a nitrogen mustard of estradiol-17β. J Clin Endocrinol Metab 1975; 41: 305-18
51. Plym-Forshell G, Müntzing J, Ek A, et al. The absorption, metabolism and excretion of estracyt (NSC89199) in patients with prostatic cancer. Invest Urol 1976; 14: 128-31
52. Gunnarsson PO, Andersson S-B, Sandberg AA, et al. Accumulation of estramustine in adipose tissue of rats and humans. Cancer Chemother Pharmacol 1991; 28: 361-4
53. Gunnarsson PO, Davidsson T, Andersson S-B, et al. Impairment of estramustine phosphate absorption by concurrent milk and food intake. Eur J Clin Pharmacol 1990; 38: 189-93
54. Forsgren B, Högberg B. Binding of a nitrogen mustard devivative of estradiol to rat ventral prostate gland and cytosol. Res Steroids 1977; 7: 431-3
55. Hoisacter PA. In vitro binding of tritiated hormone-cytostatic complexes in the cytosol of various rat tissues and the incorporation of these complexes into nuclei. Scand J Urol Nephrol 1977; 11: 135-41
56. Heyns W, De Moor P. Prostatic binding protein: a steroid-binding protein secreted by rat prostate. Eur J Biochem 1977; 78: 221-30
57. Chen C, Schilling K, Hiipakka RA, et al. Prostate a-protein: isolation and characterization of the polypeptide components and cholesterol binding. J Biol Chem 1982; 257: 116-21
58. Forsgren B, Högherg B, Gustafsson J-A, et al. Binding of estramustine, a nitrogen mustard derivative of estradiol-17β, in cytosol from rat ventral prostate. Acta Pharm Suec 1978; 15: 23-32
59. Heyns W, Peeters B, Mous J, et al. Purification and characterisation of prostatic binding protein and its subunits. Eur J Biochem 1978; 89: 181-6
60. Högberg B, Björk P, Carlström K, et al. The interaction of steroidal alkylating agents with binding components in the soluble fraction of the prostate. In: Murphy GP, Sandberg AA, editors. Prostate cancer and hormone receptors. New York: Alan R Liss Inc, 1979: 181-99
61. Bichler K-H, Flüchler SH, Nelde HJ, et al. An immunohistochemical technique for localization and semiquantitation of estramustine-binding protein (EMBP) in rat and human prostate. Prostate 1989; 14: 13-25
62. Björk P. Expression of estramustine-binding protein (EMBP) in normal and neoplastic tissues [doctorial dissertation]. Lund: Lund University, 1991
63. Bergh J, Björk P, Westlin J-E, et al. Expression of an estramustine-binding associated protein (EMBP) in human lung cancer cell lines. Cancer Res 1988; 48: 4615-9
64. Björk P, Isaacs JT, Hartley-Asp B. Estramustine binding protein (EMBP) in rat R3327 Dunning tumors: partial characterization and effect of hormonal withdrawal, hormonal replacement and cytotoxic treatment on its expression. Prostate 1991; 18: 181-200
65. Bergenheim AT, Hartman M, Bergh J, et al. Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells. J Neurooncol 1994; 22: 45-53
66. Hartley-Asp B, Gunnarsson PO. Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 1982; 127: 818-22
67. Sheridan VR, Speicher LA, Tew KD. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol 1991; 54: 268-76
68. Eklöv S, Essand M, Carlsson J, et al. Radiation sensitization by estramustine: studies in cultured human prostatic cancer cells. Prostate 1992; 21: 287-95
69. von Schoultz E, Gunnarsson PO, Henriksson R. Uptake, metabolism and proliferate effect of estramustine phosphate in human glioma cell lines. Anticancer Res 1989; 9: 1713-6
70. von Schoultz E. Malignant glioma: experimental studies with an estrogen-linked cytostatic [doctoral dissertation], Umea: Univsersity of Umea, 1990
71. Bergenheim AT, Elfverson J, Gunnarsson PO, et al. Cytotoxic effect and uptake of estramustine in a rat glioma model. Int J Oncol 1994; 5: 293-9
72. Wallin M, Deinum J, Hartley-Asp B. Estramustine phosphate inhibits microtubule assembly by binding to the mictrotubule-associated proteins. Ann NY Acad Sci 1986; 466: 423-5
73. Stearns M, Tew K. Estramustine binds to MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 1988; 89: 331-42
74. Moraga D, Rivas-Berrios A, Farias G, et al. Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and TAU. Biochem Biophys Acta 1992; 1121: 97-103
75. Dahllöf B, Billström A, Cabral F, et al. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993; 53: 4573-81
76. Bjermer L, von Schoultz E, Norberg B, et al. Estramustine inhibits monocyte phagocytosis. Prostate 1988; 13: 49-55
77. Entström KG, Grankvist K, Henriksson R. Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion. Eur J Cancer 1991; 27: 1288-95
78. Gupta R. Cross-resistance of nocodazole-resistant mutants of CHO cells toward other microtubule inhibitors: similar mode of action of benzimidazole carbamate derivatives and NSC 181928 and TN-16. Mol Pharmacol 1986; 30: 142-8
79. Jönsson G, Högberg B, Nilsson T. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt®). Scand J Urol Nephrol 1977; 11: 231-8
80. Vallbo C, Bergenheim AT, Henriksson R. Apoptosis induced in malignant glioma by estramustine in the clinical situation [abstract]. J Neurooncol 1996; 30: 106
81. Vallbo C, Bergenheim T, Bergström P, et al. Apoptotic cell death induced by estramustine in a subpopulation of glioma cells in patients with malignant glioma. Cancer Res. In press
82. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966; 29: 450-74
83. Littbrand B, Révész L. The effect of oxygen on cellular survival and recovery after radiation. Br J Radiol 1969; 42: 914-24
84. Johansson M, Bergenheim AT, Henriksson R, et al. Tumor blood flow and cytotoxic effects of estramustine and its constituents in a rat glioma. Neurosurgery 1997; 41: 237-44
85. Kjaer TB, Nilssoll T, Madsen PO. Effect of estramustine phosphate on plasma testosterone during treatment of carcinoma of the prostate. Urology 1975; 5: 802-4
86. Küss R, Khoury S, Richard F, et al. Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 1980; 52: 29-33
87. McMillin JM, Seal US, Doc RP. Effect of oral estramustine phosphate on pituitary, gonodal, and adrenal function in the green monkey. Invest Urol 1977; 15: 151-4
88. Korfsmeier K-H, Schulte-Fischedick R. Effects of estramustin phosphate on hypothalamus and hypophysis of the rat [abstract], Acta Anatomica 1981; 111: 78
89. Lerclercq G, Heusón J-C. Biochemical assays for the selection of cytotoxic-linked estrogens with potential therapeutic activity. Cancer Treat Rep 1978; 62: 1255-7
90. Slack NH, Murphy GP. Clinical toxicity and long-term results of Emcyt therapy for prostatic cancer. Urology 1984; Suppl. 23: 73-7
91. Blomböck M, Hedlund PO, Söwe U. Changes in blood coagulation and fibrinolysis in patient on different treatment regimens for prostate cancer: predictors for cardiovascular complications? Thrombosis Res 1988 Jan; 44 (1): 11-121
92. Müntzing J, Gunnarsson K. Preclinical pharmacology and toxicology of estramustine phosphate. Urology 1984; 23 Suppl. 6: 6-10
93. Sumi N, Yoshida H, Nakai K, et al. Estramustine phosphate disodium (EMP). Oyo Yakuri 1980; 20: 757-802
94. Sumi N, Kameyama K, Nishiguchi Y, et al. Estramustine phosphate disodium (EMP). Oyo Yakuri 1981; 21: 549-86